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Constitutive nuclear factor kB (NF-kB) activation is a
hallmark of colon tumor growth. Cyclin-dependent
kinases (CDKs) are critical cell-cycle regulators,
and inhibition of CDK activity has been used suc-
cessfully as anticancer therapy. Here, we show that
the NFE2L3 transcription factor functions as a key
regulator in a pathway that links NF-kB signaling to
the control of CDK1 activity, thereby driving colon
cancer cell proliferation. We found that NFE2L3
expression is regulated by the RELA subunit of
NF-kB and that NFE2L3 levels are elevated in pa-
tients with colon adenocarcinoma when compared
with normal adjacent tissue. Silencing of NFE2L3
significantly decreases colon cancer cell prolifera-
tion in vitro and tumor growth in vivo. NFE2L3 knock-
down results in increased levels of double homeobox
factor 4 (DUX4), which functions as a direct inhibitor
of CDK1. The discovered oncogenic pathway gov-
erning cell-cycle progression may open up unique
avenues for precision cancer therapy.
INTRODUCTION
Dysfunctional transcriptional and signaling networks have a
fundamental role in colorectal cancer (CRC), one of the most
common and fatal malignancies worldwide (Kuipers et al.,
2015). Different molecular CRC subtypes have been identified,
and understanding of the underlying pathogenesis of CRC for-
mation is crucial for predicting prognosis and treatment
response (De Sousa E Melo et al., 2013). The formation of CRC
includes hereditary elements, but, in most cases, is sporadic
and forms gradually over several years through the adenoma-
carcinoma sequence. Mutations in APC, KRAS, and TP53, in
conjunction with chromosomal instability, have been implicatedCell Rep
This is an open access article under the CC BY-Nin CRC development; nevertheless, other pathways can drive
tumorigenesis as well (Brenner et al., 2014; Cancer Genome
Atlas Network, 2012). Activation of the nuclear factor kB
(NF-kB) transcription factor has a critical role in many cancer
processes, including inflammation, growth, angiogenesis, inva-
sion, metastasis, and resistance (Aggarwal and Sung, 2011). In
addition, NF-kB is involved in the initiation and progression of
CRC (Karin et al., 2002; Vaiopoulos et al., 2013). Multiple path-
ways associated with uncontrolled cell proliferation, including
phosphatidylinositol 3-kinase (PI3K)-AKT-mechanistic target of
rapamycin (mTOR), have been linked to NF-kB signaling (Dan
et al., 2008). NF-kB also controls the levels of key cell-cycle reg-
ulators, such as cyclin D1, MYC, and cyclin-dependent kinases
(CDKs) (Hinz et al., 1999; Karin et al., 2002; La Rosa et al.,
1994; Perkins et al., 1997). Overexpression of NF-kB strongly
correlates with worse overall survival of CRC patients (Wu
et al., 2015). Moreover, increased levels of tumor necrosis factor
(TNF), a cytokine inducing NF-kB activity, have been associated
with advanced stages of CRC (Al Obeed et al., 2014), and
chronic TNF exposure contributes to a pro-malignant phenotype
(Szlosarek et al., 2006).
Cap’n’collar (CNC) transcription factors have crucial roles in a
variety of cellular processes, including the stress response and
carcinogenesis, with its most extensively investigated family
member being the NFE2L2 (NRF2) protein (DeNicola et al.,
2011). NFE2L3 (NRF3), a close homolog of NFE2L2, is less well
studied and its functions remain largely unknown (Chevillard
and Blank, 2011), but some recent findings linked the transcrip-
tion factor to apoptosis and different types of cancer (Chowd-
hury et al., 2017; Siegenthaler et al., 2018; Sun et al., 2019;
Wang et al., 2017, 2018). Similar to other CNC proteins,
NFE2L3 dimerizes with small MAF transcription factors, and
the resulting complexes bind to the antioxidant response
element (ARE) type of DNA-recognition sites (Che´nais et al.,
2005). NFE2L3 transcript and protein levels are induced by
TNF (Che´nais et al., 2005). NFE2L3 is a tightly regulated and
post-translational-modified protein with a rapid turnover (Nouhi
et al., 2007), and FBXW7 ubiquitin ligase and GSK3B haveorts 29, 1469–1481, November 5, 2019 ª 2019 The Authors. 1469
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Upregulation of NFE2L3 Corre-
lates with Poor Prognosis for Patients with
Colon Cancer
(A) Colon adenocarcinoma (COAD) cancer gene
expression data (mRNA, normalized RNA-seqV2
RSEM) were retrieved from TCGA database using
the cBioPortal for cancer genomics. Boxplots
represent the first and third quartiles and median
values; whiskers represent the 5th and 95th per-
centiles; Mann-Whitney U test, ***p < 0.001.
(B) Quantitative real-time PCR analysis of NFE2L3
expression in colon cancer tissues and the adja-
cent counterpart from five patients with colon
adenocarcinoma (means ± SD).
(C) Representative IHC images of human colon
adenocarcinoma TMA stained for NFE2L3. The
scale bar represents 200 mm; on the right side,
magnification 380; S, stroma; NG, normal gland;
AG, adenocarcinoma gland.
(D) Classification and quantification of samples
according to the intensity of staining of NFE2L3
expression (n = 75).
(E) Distribution of the higher NFE2L3 expression
tumor samples (score 3 and 4) using the AJCC
Clinical Stage for Colorectal Cancer (Singh, 2017).been shown to control NFE2L3 degradation (Kannan et al.,
2015). Subcellular fractionation experiments revealed the
presence of three forms of NFE2L3: a primarily endoplasmic re-
ticulum (ER)-bound N-glycosylated A form, a cytoplasmic non-
glycosylated B form, and a faster migrating, largely nuclear C
form (Kannan et al., 2015; Nouhi et al., 2007). In this study, we
aimed to unravel the cellular network governing NFE2L3 regula-
tion and function. We report that NFE2L3 acts as a central player
in an identified NF-kB signaling pathway that controls colon can-
cer cell growth.
RESULTS
NFE2L3 Controls Colon Tumor Growth
We investigated the mRNA levels of the NFE2L3 transcription
factor in normal and tumoral tissues using The Cancer Genome
Atlas (TCGA) database (Figure 1A). NFE2L3 transcripts were
significantly upregulated in colon adenocarcinoma (n = 459)
compared with normal samples (n = 41). Similar results were
observed in BioGPS and Oncomine datasets (Figure S1) as
well as upon analysis of NFE2L3mRNA levels in a set of five co-1470 Cell Reports 29, 1469–1481, November 5, 2019lon adenocarcinomas and normal
adjacent tissues by quantitative real-
time PCR (Figure 1B). To evaluate
NFE2L3 protein levels, we performed
immunohistochemistry (IHC) staining on
a tissue microarray (TMA) of 75 patients,
revealing greater expression of NFE2L3
in colon adenocarcinoma compared
with matched normal adjacent tissue
(Figure 1C). We classified the samples
into four groups with increasing staining
intensity from weakest (score 1) to stron-gest (score 4) (Figure 1D). We observed that NFE2L3 expression
wasweak, falling into groups 1 and 2 inmost adjacent normal tis-
sues (95%). In contrast, NFE2L3 levels were high, falling into
groups 2–4 in most colon tumor tissues (97%; Figure 1D). In co-
lon adenocarcinoma glands, we observed a strong nuclear and
strong rimmed perinuclear pattern for NFE2L3, which diffuses
across their cytoplasm, whereas, in normal glands, the staining
is mostly perinuclear and cytoplasmic (Figure 1C). We also found
that the high expression of NFE2L3 in tumor samples is corre-
lated with the advanced stages of the disease, except for the
metastasis stage (Figure 1E). Together, these results suggest
that NFE2L3 might have a critical role in colon adenocarcinoma
development and may be linked to major oncogenic pathways.
Silencing NFE2L3 Inhibits Colon Cancer Cell
Proliferation
To assess the role of NFE2L3 in colon cancer, we depleted
NFE2L3 expression with two different lentiviral short hairpin
RNAs (shRNAs) in distinct colon cancer cell lines HCT116 and
HT29. Efficient knockdown of NFE2L3 was confirmed by quanti-
tative real-time PCR and immunoblot (Figures 2A and 2B) and
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Figure 2. NFE2L3 Is Required for Colon Cancer Cell Growth In Vitro and In Vivo
(A) Quantitative real-time PCR analysis of NFE2L3 mRNA in HCT116 and HT29 cells transduced with NFE2L3-specific shRNAs (shNFE2L3-1 or -2) presented
relative to NFE2L3 mRNA expression in cells transduced with a non-targeting control (NTC) shRNA.
(B) Immunoblot analyses of NFE2L3 in the cells described in (A).
(C) Immunoblot analyses of NFE2L3 from total lysate or nuclear extraction in HCT116 cells. Arrows indicate the A, B, and C form of NFE2L3.
(D) Cell viability in HCT116 cells assessed by MTT assay after 72 h. Error bars are means ± SEM, n = 3 independent experiments, ***p < 0.001, two-sided
Student’s t test.
(E and F) Representative images (E) and quantification (F) of a colony-formation assay of the HCT116 and HT29 cells. For each cell line, all dishes were fixed at the
same time, stained, and photographed. Error bars are means ± SEM, n = 3 independent experiments, ***p < 0.001, two-sided Student’s t test.
(G) Incorporation of BrdU in HCT116 and HT29 cells as measured by ELISA after treatment for 16 h. Error bars are means ± SEM, n = 3 independent experiments,
*p < 0.05, **p < 0.01, ***p < 0.001, NS, not significant; two-sided Student’s t test.
(H) Quantitative real-time PCR analysis ofMKI67mRNA in HCT116 cells. Error bars are means ± SEM, n = 3 independent experiments, *p < 0.05, **p < 0.01, two-
sided Student’s t test.
(I and J) Representative images (I) and quantification (J) of HCT116 and HT29 cells by soft agar assay. Error bars are means ± SEM, n = 3 independent ex-
periments, ***p < 0.001, two-sided Student’s t test.
(legend continued on next page)
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affected the abundance of all three previously characterized
NFE2L3 A, B, and C forms (Figure 2C) (Nouhi et al., 2007). We
observed a strong reduction in cell numbers three days after
plating when NFE2L3 was knocked down, and colony formation
was significantly reduced (Figures 2D–2F). No changes in
apoptosis were observed by flow cytometry using Annexin V
and propidium iodide (PI) staining (Figure S2). In contrast,
reduced numbers of bromodeoxyuridine (BrdU)-incorporating
cells, as well as a decrease in the mRNA expression of the
MKI67 (Ki67) gene coding for a major cell-proliferation marker,
showed that NFE2L3 functions as a positive regulator of colon
cancer cell growth (Figures 2G and 2H). To model physiological
conditions, we evaluated anchorage-independent colon cancer
cell growth in a soft agar assay (Figures 2I and 2J) and prolifera-
tion of HCT116 cells in vivo in a mouse xenograft model (Fig-
ure 2K and 2L). In both settings, NFE2L3 knockdown severely
compromised cell growth. Reduced MKI67 staining in xeno-
grafts of NFE2L3 knockdown samples confirmed that this effect
was largely due to reduced cell proliferation in vivo (Figures 2M
and 2N). Altogether, these results establish a crucial role for
NFE2L3 as a promoter of colon cancer cell proliferation and tu-
mor growth.
RELA Functions as a Positive Regulator of NFE2L3
Expression
Our previous studies had shown that TNF increases NFE2L3
levels (Che´nais et al., 2005). To determine the molecular mecha-
nisms underlying NFE2L3 upregulation in colon cancer cells, we
treated the cells with inhibitors of different signaling pathways
upon TNF activation and assessed NFE2L3 levels. Specifically,
we examined the effect of inhibiting the MEK1/2 (PD98059),
p38 (SB203580), PI3K/AKT (LY294002), and NF-kB (BAY 11-
7082) pathways because these signaling molecules have been
previously linked to colon tumorigenesis (Karin, 2006; Cancer
Genome Atlas Network, 2012). Although MEK1/2, p38, and
PI3K/AKT inhibitors had no or minimal effect, we observed that
the inhibitor of NF-kB signaling strongly reduced NFE2L3 levels
(Figure 3A). NF-kB pathway is involved in inflammation, tumor
survival, migration, and proliferation of colon cancer cells (Ben-
Neriah and Karin, 2011; Karin, 2006; Wang et al., 2009). In vivo,
colorectal cancer cells are exposed to a variety of cytokines
released from the tumor stroma, including known activators of
NF-kB signaling, such as TNF, which enhances the growth of co-
lon cancer cells by the activation of oncogenic pathways (Ben-
Neriah and Karin, 2011; Wang et al., 2009). Treatment of colon
cancer cell lines with TNF increased NFE2L3 protein levels;
this effect was strongly diminished upon treatment of cells with
two mechanistically different inhibitors of NF-kB signaling (Fig-
ures 3B and 3C): BAY 11-7082 blocks TNF-induced NFKBIA
(IkBa) phosphorylation, and JSH-23 functions as an inhibitor of
NF-kB transcriptional activity (Pierce et al., 1997; Shin et al.,
2004). The NF-kB transcription factor family comprises homo-(K and L) Representative gross images (K) of the xenograft tumors at the endp
implanted HCT116 cells expressing a NTC shRNA or NFE2L3-specific shRNAs (s
**p<0.01, Mann-Whitney U test.
(M) Representative images of NFE2L3 and MKI67 analyzed by immunohistochem
(N) Quantification of MKI67 analyzed by immunohistochemical staining. The scale
cells. Error bars are means ± SEM, n = 3 mice per group, ***p < 0.01, two-sided
1472 Cell Reports 29, 1469–1481, November 5, 2019and heterodimeric complexes that are formed by the combina-
tion of five different subunits, including RELA (p65), RELB,
REL, NFKB1 (p50), and NFKB2 (p52) (Karin, 2006; Vaiopoulos
et al., 2010). We found that shRNA-mediated knockdown of
RELA significantly decreased NFE2L3 mRNA and protein
expression levels (Figures 3D, 3E, and S3A–S3C), recapitulating
the reduced growth phenotype associated with NFE2L3
silencing (Figures 3F and 3G). In contrast, downregulation of
the NF-kB subunits REL, RELB, NFKB1, or NFKB2 had no effect
on NFE2L3 expression (Figure S3). Consistent with this, data
from the ENCODE project consortium showed binding of the
RELA subunit of NF-kB to the first intron of NFE2L3 (Figure S4A)
(ENCODE Project Consortium, 2012), which we confirmed by
chromatin immunoprecipitation (ChIP)-qPCR analyses and lucif-
erase reporter assays (Figures 3H–3J). To assess whether low
NFE2L3 levels contribute to the inhibition of proliferation
observed upon silencing of RELA in colon cancer cell lines, we
overexpressed the NFE2L3 full form (generating A, B, and C),
the ER/cytoplasmic A–B forms, or the nuclear C form of
NFE2L3 and found that both expression of the full or C form of
NFE2L3, but not the A–B form, partially rescued the phenotype
of reduced colon cancer cell growth upon RELA knockdown,
as confirmed by BrdU incorporation (Figures S4B and S4C).
We conclude that RELA positively regulates NFE2L3 expression
and thus may contribute to its protumoral effects.
Identification of DUX4 as a Negatively Regulated Target
of NFE2L3
To investigate the mechanistic link between NFE2L3 and cell
proliferation, we searched for genes controlled by NFE2L3 that
maymediate its effect on colon cancer cell proliferation. To iden-
tify transcriptional targets, we carried out ChIP-sequencing with
NFE2L3-specific antiserum in TNF-treated HCT116 cells.
Among the identified potential NFE2L3 target genes, the DUX4
gene emerged as a highly interesting candidate because it had
been previously linked to the cell cycle (Bosnakovski et al.,
2008). In addition, DUX4 ranked as the top gene to have its
NFE2L3 peaks converge when combining both fold enrichment
and distance to the transcription start site (TSS) (Figure 4A).
The binding of NFE2L3 to the DUX4 locus was corroborated by
ChIP-qPCR analysis (Figure 4B), and knockdown of NFE2L3 re-
sulted in a significant increase in DUX4 mRNA (Figure 4C) and
protein levels (Figure 4D). Reintroduction of the full form and
the nuclear C form of NFE2L3 by lentiviral transduction reduced
DUX4 levels and partially rescued cellular proliferation (Figures
4E and 4F). Consistent with these data, inhibition of NF-kB
by RELA-knockdown or JSH-23 inhibitor treatment reduced
NFE2L3 and increased DUX4 protein levels (Figures 4G and
4H). Thus, DUX4 is repressed by NFE2L3 and might have a
role in the effects of NFE2L3 on cell proliferation. A gain-of-func-
tion phenotype of DUX4 has been linked to facioscapulohumeral
muscular dystrophy (FSHD) (Bosnakovski et al., 2008; Gabellinioint and growth curves (L) of xenograft tumors derived from subcutaneously
hNFE2L3-1 or -2). Error bars are means ± SEM, n=9 mice per group, *p<0.05,
ical staining.
bar represents 100 mm. The bar graph shows the percentage of MKI67-positive
Student’s t test.
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Figure 3. NFE2L3 Is Regulated by the RELA Subunit of NF-kB
(A) HCT116 cells were pretreatedwith PD98059 (20 mM), SB203580 (20 mM), LY294002 (20 mM), and BAY 11-7082 (10 mM) for 2 h, followed by stimulation with TNF
(20 ng/mL) for 6 h. The expression of NFE2L3 was examined by immunoblot.
(B) Immunoblot analysis of NFE2L3 in HCT116 and HT29 cells pretreated with BAY 11-7082 (10 mM, 2 h) followed by stimulation with TNF (20 ng/mL, 6 h).
(C) Immunoblot analysis of NFE2L3 in HCT116 and HT29 cells pretreated with JSH-23 (50 mM, 16 h) followed by stimulation with TNF (20 ng/mL, 6 h).
(legend continued on next page)
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et al., 2002), but its function in cancer remains unclear, despite
some recent data showing that DUX4 is deregulated in acute
lymphoblastic leukemia and can control the migration of mesen-
chymal stem cells (Dmitriev et al., 2016; Yasuda et al., 2016;
Zhang et al., 2016). We found that lentiviral overexpression of
DUX4, driven by a strong (cytomegalovirus [CMV]), as well as
weak, promoter (ubiquitin C [UBC]), is toxic and leads to the
death of most cells within 24–48 h (data not shown). To assess
whether elevated DUX4 levels contribute to the inhibition of pro-
liferation observed upon silencing of NFE2L3 in colon cancer cell
lines, we thus knocked downDUX4 and observed that combined
NFE2L3 and DUX4 depletion partially rescued the phenotype of
reduced colon cancer cell growth, as confirmed by BrdU incor-
poration and soft agar assays (Figures 4I–4L). We also analyzed
DUX4mRNA levels in colon adenocarcinomas and normal adja-
cent tissue specimens. We found decreased DUX4 transcript
levels in four of the five colon adenocarcinomas samples, thus
correlating well with NFE2L3 expression (Figures 1B and S5A).
Overall, these data suggest that DUX4 mediates in part the pro-
liferation phenotype observed upon modulation of RELA and/or
NFE2L3 levels.
Role of DUX4 as a Direct Inhibitor of CDK1 Activity
To understand how DUX4 might affect cell proliferation, we
searched for DUX4-interacting proteins in colon cancer cells
by performing immunoprecipitation followed bymass spectrom-
etry analysis in HCT116 cells. Using ReactomePA (Yu and He,
2016), we identified different cell-cycle regulators, including cy-
clin-dependent kinase 1 (CDK1), as potential binding partners for
DUX4, providing a rationale for the role of NFE2L3 in the control
of colon cancer cell proliferation (Figure S5B; Table S1). We
confirmed the interaction between DUX4 and CDK1 by co-
immunoprecipitation of epitope-tagged CDK1 and DUX4 co-ex-
pressed in HCT116 cells (Figure 5A). In parallel, we performed
co-immunoprecipitation experiments with three additional
CDKs (CDK2, 4, and 6) to verify the specificity of the DUX4-
CDK1 interaction (Figure 5A). Clearly, interaction between
DUX4 and CDK1 is stronger than that with other members of
the CDK family. Immunoprecipitation of endogenous CDK1
from cells expressing NFE2L3 shRNA, which increases endoge-
nous DUX4 protein levels, confirmed the interaction between this
kinase and the DUX4 protein (Figure 5B). Furthermore, we de-
signed an in silico model of the DUX4-CDK1 complex using the
ZDOCK server (Figures 5C, 5D, and S6A). Based on the complex
CDK1-cyclin B1-CKS2 available on the PDB, we separated the
three proteins to generate a model for DUX4-CDK1 interactions.(D) Quantitative real-time PCR analysis of RELA and NFE2L3mRNA in HCT116 ce
Error bars are means ± SEM, n = 3 independent experiments, *p < 0.05, **p < 0.
(E) Immunoblot analysis of RELA and NFE2L3 in HCT116 and HT29 cells transdu
(F) BrdU incorporation measured by ELISA in HCT116 and HT29 cells transduced
means ± SD, n = 2 independent experiments, ***p < 0.001, two-sided Student’s
(G) Quantification of soft agar assay of HCT116 cells transduced with a NTC shR
independent experiments, ***p < 0.001, two-sided Student’s t test.
(H) Localization of a RELA binding site in the NFE2L3 gene locus.
(I) ChIP analyses were performed in HCT116 and HT29 cells using anti-RELA anti
enrichment was quantified by qPCR. Error bars are means ± SEM, n = 3 indepen
(J) Luciferase assay: 293T cells were transfectedwith the indicated plasmids. After
Error bars are means ± SEM, n = 3 independent experiments, **p < 0.01, NS, no
1474 Cell Reports 29, 1469–1481, November 5, 2019The model predicts that DUX4 binds CDK1 at the same location
as CDC28 protein kinase regulatory subunit 2 (CKS2), and we
identified the amino acids implicated in this binding (Brown
et al., 2015) (Figure S6B). A series of interactions are involved
in the formation of the complex, including hydrogen bonds
and electrostatic as well as van der Waals interactions. We
compared the sequences of CDK1 with CDK2, CDK4, and
CDK6 to illustrate the variations among the different members
of the CDK protein family and the difference of binding with
DUX4. Our model suggests that the binding between DUX4
and CDK1 is mediated by a series of residues present in
conserved domains of the CDK family but the variability of
some amino acidsmay explain the difference of affinity observed
in Figure 5A (Figure S6C). Based on these in silico models, we
generated three different mutants to characterize the domain
of DUX4 implicated in the interaction with CDK1 (Figure 5E).
Deletion of amino acids from position 111–131 strongly, and
deletion from position 141–180moderately, reduced the interac-
tion with CDK1, whereas deletion of aa 381–400 had no effect
(Figure 5F). We investigated more precisely the amino acids
implicated in the interaction between DUX4 and CDK1 (Fig-
ure S6B), and based on those predictions, we generated two
mutants, Arg117Ala and Phe118Ala, of DUX4. By immunopre-
cipitation, we observed that the interaction between CDK1 and
those DUX4 mutants is reduced compared with the wild-type
form of the protein (Figure 5G). Next, we performed glutathione
S-transferase (GST) pull-down comparing the binding of DUX4
to CDK1 and the CDK1-cyclin B complex (Figures 6A and 6B).
Our data showed that DUX4 preferentially interacts directly
with CDK1 alone and only minimally with the CDK1-cyclin B
complex. In addition, we quantitatively assessed the interaction
between DUX4-GST and CDK1-His tag by microscale thermo-
phoresis (MST). We determined a KD (dissociation constant) of
1.7 ± 0.1 mM for the binding of DUX4 to CDK1 (Figure 6C). GST
alone was used as negative control. Together, our results show
that the DUX4 protein directly interacts with CDK1.
To determine whether DUX4 inhibits the activity of CDK1, we
immunoprecipitated CDK1 and assessed its in vitro kinase activ-
ity on recombinant histone H1 protein (Ruiz et al., 2010). We
showed that CDK1 activity, measured by H1 phosphorylation,
was strongly decreased in cells after NFE2L3 knockdown but
was not altered in control cells, after a single DUX4 or a com-
bined NFE2L3/DUX4 knockdown (Figure 6D). Cell-cycle profiling
and high levels of NUP98 also showed that silencing of NFE2L3
leads to an accumulation of cells in the G2/M phase, which is
controlled by the CDK1-cyclin B complex (Laurell et al., 2011)lls transduced with a NTC shRNA or RELA-specific shRNAs (shRELA-1 or -2).
01, ***p < 0.001, two-sided Student’s t test.
ced with a NTC shRNA or RELA-specific shRNAs (shRELA-1 or -2).
with a NTC shRNA or RELA-specific shRNAs (shRELA-1 or -2). Error bars are
t test.
NA or a RELA-specific shRNA (shRELA-1). Error bars are means ± SEM, n = 3
body. An immunoglobulin G (IgG) antibody was used as negative control. Fold
dent experiments, **p < 0.01, two-sided Student’s t test.
incubation for 24 h, luciferase activity wasmeasured and normalized toRenilla.
t significant; two-sided Student’s t test.
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Figure 4. NFE2L3 Functions as a Repressor of DUX4
(A) Example of NFE2L3 ChIP-sequencing traces in HCT116 cells.
(B) ChIP-qPCR validation of NFE2L3 binding to the DUX4 locus using NFE2L3 or IgG control antibody. Error bars are means ± SEM, n = 3 independent ex-
periments, **p < 0.01, two-sided Student’s t test.
(C) Expression ofDUX4mRNA assayed by quantitative real-time PCR in HCT116 cells. Error bars are means ± SEM, n = 3 independent experiments, ***p < 0.001,
two-sided Student’s t test.
(D) Immunoblot analysis of NFE2L3, DUX4, and tubulin in HCT116 and HT29 cell lines transduced with a NTC shRNA or NFE2L3-specific shRNAs (shNFE2L3-1
or -2).
(E) Immunoblot analysis of HCT116 cells expressing NFE2L3 shRNA (shNFE2L3-2) or a NTC shRNA upon reexpression of the different forms of NFE2L3 (see
Figure 2C for description of A, B, or C forms).
(legend continued on next page)
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(Figures 6E–6G). The decrease of CDK1 activity might thus
explain the reduced colon cancer cell proliferation upon knock-
down of NFE2L3. In conclusion, our data reveal a link between
the NF-kB signaling pathway and cell-cycle regulation, with
NFE2L3 acting as a repressor of the CDK1 inhibitor DUX4
(Figure 6H).
DISCUSSION
Colorectal cancer ranks as the third most common cancer
worldwide (Kuipers et al., 2015). The underlyingmolecular mech-
anisms of CRC pathology are complex, comprising a variety of
genetic and epigenetic factors that control the proliferation rate
of cells, their differentiation, and proneness to undergo cell death
(Cancer Genome Atlas Network, 2012; Vinson et al., 2016). We
found that NFE2L3 levels are substantially elevated in human co-
lon adenocarcinoma tissue specimens when compared with
healthy adjacent tissue, suggesting a possible role for this tran-
scription factor in colon tumorigenesis. The signaling cascade
discovered in our study comprises the extensively analyzed
NF-kB and NFE2L3, a factor of yet largely unknown function.
These transcriptional regulators are linked to the central cell cy-
cle regulator CDK1, via the control of DUX4, a protein that has
previously primarily been analyzed in the context of muscle
biology (Chevillard and Blank, 2011; Gabellini et al., 2002; Zhang
et al., 2017).
In our earlier studies, we reported that NFE2L3 expression is
positively controlled by TNF at both the transcript and protein
levels (Che´nais et al., 2005). In addition, many studies have
linked the NF-kB pathway to TNF signaling (Li et al., 2015).
Our data identified NFE2L3 as a novel downstream effector
of RELA, as we found that other NF-kB family members are
not involved in the regulation of NFE2L3. As confirmed by
ChIP analysis, the control of NFE2L3 transcription by NF-kB
is direct. The regulation by RELA is robust because inhibition
of the transcriptional activity of NF-kB, NFKBIA phosphoryla-
tion, or knockdown of RELA all recapitulated the phenotype
observed upon NFE2L3 silencing. This is of interest because
RELA is constitutively activated in human CRC tissue (Reza-
pour et al., 2016). Additional studies revealed that NOTCH1
levels, which were found to be an independent predictor of
prognosis for patients with CRC, correlated with RELA status
(Chu et al., 2011). NF-kB is also known to modulate Wnt
signaling, whose activation is a common event in colon cancer
initiation: ablation of RELA in intestinal epithelial cells delays the
expansion of crypt stem cells, whereas elevated NF-kB
signaling results in the dedifferentiation of non-stem cells into(F) BrdU incorporation in HCT116 cells treated as in (E) assessed by ELISA. Error
***p < 0.001, NS, not significant; two-sided Student’s t test.
(G) Immunoblot analysis of NFE2L3, DUX4, and tubulin in HCT116 cells transduc
(H) Immunoblot analysis of NFE2L3, DUX4, and tubulin in HCT116 cells treated w
(I) Immunoblot analysis of HCT116 cells transduced with a combination of vectors
shDUX4.
(J) BrdU incorporation in HCT116 cells treated as in (I) assessed by ELISA. Erro
significant; two-sided Student’s t test.
(K and L) Representative images (K) of soft agar assay of HCT116 cells treated a
experiments, **p < 0.01, ***p < 0.001, NS, not significant; two-sided Student’s t
1476 Cell Reports 29, 1469–1481, November 5, 2019tumor-initiating cells (Schwitalla et al., 2013). These data illus-
trate the importance of RELA in CRC development. The identi-
fication of NFE2L3 as a RELA target provides novel avenues to
dissect the functions of NF-kB signaling pathway in colon can-
cer pathology.
NFE2L3 has been first identified almost 20 years ago but its
function remains largely unknown (Chevillard and Blank, 2011).
Mouse model experiments revealed that NFE2L3 has a protec-
tive function in carcinogen-induced lymphomagenesis (Chevil-
lard et al., 2011). Recent studies implicated NFE2L3 in various
types of malignancies, including pancreatic, thyroid, and breast
cancer (Sun et al., 2019; Wang et al., 2017, 2018). Our results
demonstrate a growth-promoting function of NFE2L3 in colon
cancer cells, which is likely mediated by the nuclear C form of
the transcription factor. Our ChIP-seq analysis, together with
molecular analyses, revealed that NFE2L3 serves as a key regu-
lator for the control of DUX4 expression. The DUX4 protein has
mainly been investigated for its role in FSHD. The DUX4 gene,
located in a transcriptionally silent repeat region, is present at
high levels in FSHD muscle because of chromatin changes,
contributing to the phenotype, but the exact mechanisms remain
obscure (Eidahl et al., 2016). Of interest, DUX4 also contributes
to leukemia and round-cell sarcoma because of somatic
chromosomal rearrangements resulting in DUX4-IGH and CIC-
DUX4 fusions, respectively (Kawamura-Saito et al., 2006; Ya-
suda et al., 2016). Overexpression of DUX4 is toxic in many
different cellular models and also results in increased sensitivity
to oxidative stressors (Bosnakovski et al., 2008). Interestingly, in
the context of colon cancer cells, upregulation of endogenous
DUX4 protein upon NFE2L3 or RELA knockdown, results in a
diminution of cell proliferation, but we did not observe any
obvious toxicity to the cells, as measured by Annexin V/PI stain-
ing (Figure S2). However, overexpression of exogenous DUX4,
even driven by a weak promoter, is highly toxic to the cells in
our colon cancer cell model.
How is the function of NFE2L3 transcriptional regulator
coupled to cell proliferation in our experimental model? Our
studies revealed an unanticipated link, showing that DUX4 is
able to interact with CDK1, a crucial cell-cycle regulator, as
evidenced by immunoprecipitation, followed by mass spec-
trometry analysis. This result was confirmed by co-immunopre-
cipitation (coIP) studies of exogenous and endogenous
proteins, by performing GST pull-down assays and by
measuring the KD of the interaction between DUX4 and CDK1,
which is in the low micromolar range. In silico analysis high-
lighted amino acids potentially implicated in the interaction be-
tween DUX4 and CDK1, and based on these theoretical models,bars are means ± SEM, n = 3 independent experiments, *p < 0.05, **p < 0.01,
ed with a NTC shRNA or a RELA-specific shRNA (shRELA-1).
ith DMSO or JSH-23 (50 mM, 16 h).
driving non-silencing controls (NTC shRNA or pLV scramble), shNFE2L3-1, or
r bars are means ± SEM, n = 3 independent experiments, *p < 0.05, NS, not
s in (I) and its quantification (L). Error bars are means ± SD, n = 2 independent
test.
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Figure 5. DUX4 Interacts with CDK1
(A) coIP of pCMV-neo-CDK1-HA, pCMV-neo-CDK2-HA, pCMV-neo-CDK4-HA, pCMV-neo-CDK6-HA, and pCMV6-entry-Myc-Flag or pCMV6-DUX4-Myc-Flag
from HCT116-transfected cell lysates. Samples and lysates were analyzed by immunoblot.
(B) Immunoprecipitation of lysates from HCT116 cells transduced with shNFE2L3-1 using anti-CDK1 antibody. Samples and lysates were analyzed by immu-
noblot.
(C) Protein structure of the DUX4-CDK1 complex obtainedwith ZDOCK server. Amino acids implicated in the binding of DUX4 to CDK1 are highlighted and shown
in detail in Figure S6B.
(D) DUX4-CDK1 interactions showing DUX4 (blue) and CDK1 (green) amino acids.
(E) Representation of the DUX4 mutants and their different regions.
(F) HCT116 cells were transiently transfected with vectors expressing HA-tag or CDK1-HA and Myc-tag, or DUX4(WT)-Myc, or DUX4(D111-131)-Myc, or
DUX4(D141-180)-Myc, or DUX4(D381-400)-Myc. Proteins were immunoprecipitated with an anti-HA antibody, and samples were analyzed by immunoblotting.
(G) HCT116 cells were transiently transfected with vectors expressing HA-tag or CDK1-HA and Myc-tag, DUX4(WT)-Myc, DUX4(Arg117Ala)-Myc, or
DUX4(Phe118Ala)-Myc. Proteins were immunoprecipitated with an anti-HA antibody, and samples were analyzed by immunoblotting.
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Figure 6. DUX4 Interacts Directly with
CDK1 and Inhibits Its Activity
(A) In vitro GST pull-down of recombinant GST or
GST-CDK1/GST-cyclin B1 and recombinant
DUX4-Myc-FLAG using glutathione beads.
(B) In vitro GST pull-down of recombinant GST or
GST-CDK1 and recombinant DUX4-Myc-FLAG
using glutathione beads. Lysate and pull-down
were immunoblotted for the indicated proteins
(signals shown for each antibody are from the
same exposition time).
(C) Microscale thermophoresis analysis for
dissociation constant determination between
GST-DUX4 and human CDK1. KD value is shown.
The different-colored lines correspond to the
different replicates of the MST dose-response
curves (n = 3). GST alone was used as a negative
control.
(D) Immunoblots of indicated proteins after in vitro
kinase assay containing ATP, His-H1, and immu-
noprecipitated CDK1 complexes from HCT116
cells transduced with a NTC shRNA, a NFE2L3-
specific shRNA (shNFE2L3-1), a DUX4-specific
shRNA (shDUX4), or both (shNFE2L3-1, shDUX4).
(E) Cell-cycle distribution of HCT116 cells trans-
duced with a NTC shRNA or NFE2L3-specific
shRNAs (shNFE2L3-1 or -2) assessed by flow
cytometry after PI staining.
(F) Percentage of HCT116 and HT29 cells treated
as in (E) in the G2/M phase. Error bars are means ±
SEM, n = 3 independent experiments, *p < 0.05,
**p < 0.01, two-sided Student’s t test.
(G) Immunoblot analysis of NUP98 and tubulin in
HCT116 cells as in (E).
(H) Model for the pathway of the RELA and
NFE2L3 transcription factors controlling cell-cycle
progression via the regulation of DUX4 and CDK1.we found that the region between aa 111 and 180 mediates the
DUX4-CDK1 interaction. Our in silico analysis predicted that the
DUX4 residues Arg117 and Phe118 are among the key amino
acids mediating that interaction (Figure S6). We generated point
mutants of DUX4 in these two residues and indeed observed a
reduced interaction between these two mutants and CDK1 in
coIP studies (Figure 5G). The molecular mechanisms controlling
cell-cycle progression are complex, requiring the coordinated
action of a series of regulatory proteins, including major tumor
suppressors, such as the cyclin-dependent kinase inhibitor 1A
(CDKN1A; p21), cyclin-dependent kinase inhibitor 2A (CDKN2A;
p16), and retinoblastoma (RB) proteins (Asghar et al., 2015; Lig-
gett and Sidransky, 1998). Deficient control of the cell cycle may
lead to transformation of normal cells and enhance tumor devel-
opment. CDK1-cyclin B1, a serine/threonine kinase complex
regulated through protein-protein interactions and post-tran-
scriptional modifications, has a major role in G2/M phase tran-
sition (Santamarı´a et al., 2007). With respect to the mechanism
explaining the effect of NFE2L3 on cell-cycle progression, we
hypothesize that DUX4 binds directly to CDK1 and limits the1478 Cell Reports 29, 1469–1481, November 5, 2019interaction with its targets that are phos-
phorylated by the enzyme (Brown et al.,
2015). As the overexpression of exoge-nous wild-type DUX4, driven by a regular, and even by a
weak, promoter, is highly toxic to the cells, we could not use
wild-type DUX4, and in parallel the non-CDK binding mutants,
to determine their effect on the activity of CDK1. In addition,
our GST pull-down data suggest that DUX4 preferentially inter-
acts with CDK1 alone. However, an assay to assess the inhibi-
tion of kinase activity with only recombinant CDK1, which is
inactive without cyclin B1, is not feasible. However, we have
shown in our in vitro kinase assay that inhibition of CDK1 is
dependent upon direct binding of DUX4 because the combined
NFE2L3/DUX4 knockdown does not lead to a decrease in H1
phosphorylation in contrast to NFE2L3 knockdown alone (Fig-
ure 6D). Nevertheless, complementary experiments are required
to determine whether DUX4 is a specific inhibitor of CDK1 or
also can inhibit the activity of other CDKs, for example, CDK2,
CDK4, or CDK6. Because of their central role in cell-cycle pro-
gression, CDKs have been a major target for cancer therapy
(Asghar et al., 2015). For example, the CDK4/6 inhibitor palbo-
ciclib has been approved recently for use in patients with
breast cancer (Finn et al., 2016). Current challenges are in the
development of highly selective agents against specific CDKs,
companion diagnostics that will enable the selection of appro-
priate patient populations, and a better understanding of the
intersection of pharmacology and biology that will provide the
basis for rational drug combinations (Asghar et al., 2015). Our
finding that DUX4, which is tightly regulated by NFE2L3, func-
tions as a direct inhibitor of CDK1, will open novel treatment op-
portunities by precision therapy, for example, by screening for
molecules that inhibit NFE2L3 activity or promote DUX4 expres-
sion in tumors.
Taken together, based on our observations, we propose the
existence of an oncogenic pathway, comprising the RELA,
NFE2L3, DUX4, and CDK1 proteins that control colon cancer
cell growth. Our study establishes a key role for the NFE2L3 tran-
scription factor that regulates cell-cycle progression by govern-
ing the expression of DUX4, a direct inhibitor of CDK1.STAR+METHODS
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pCMV6-entry-Myc-Flag Origene PS100001
pCMV6-DUX4-Myc-Flag Origene RC238145
pCMV-neo-CDK1-HA S. Van den Heuvel’s laboratory Addgene plasmid #1888
pCMV-neo-CDK2-HA S. Van den Heuvel’s laboratory Addgene plasmid #1884
pCMV-neo-CDK4-HA S. Van den Heuvel’s laboratory Addgene plasmid #1876
pCMV-neo-CDK6-HA S. Van den Heuvel’s laboratory Addgene plasmid #1868
pCMV-HA-C Clontech 635690
pcDNA3.1-Myc Genscript N/A
pcDNA3.1-DUX4(WT)-Myc Genscript N/A
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
pcDNA3.1-DUX4(D111-131)-Myc Genscript N/A
pcDNA3.1-DUX4(D141-180)-Myc Genscript N/A
pcDNA3.1-DUX4(D381-400)-Myc Genscript N/A
pcDNA3.1-DUX4(Arg117Ala)-Myc Genscript N/A
pcDNA3.1-DUX4(Phe118Ala)-Myc Genscript N/A
GST-tagged DUX4 (pGEX-6-p1) S. Harper’s laboratory N/A
Software and Algorithms
SAMtools Li et al., 2009 http://www.htslib.org
HOMER Heinz et al., 2010 http://homer.ucsd.edu/homer/
PEAKS 7.0 Bio-informatics Solutions N/A
I-TASSER Roy et al., 2010; Yang et al., 2015;
Zhang,2008
https://zhanglab.ccmb.med.umich.
edu/I-TASSER/
LOMETS Wu and Zhang, 2007 https://zhanglab.ccmb.med.umich.
edu/LOMETS/
ZDOCK 3.0.2 Mintseris et al., 2007; Pierce et al., 2011 http://zdock.umassmed.edu
Statistica software StatSoft N/ALEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Volker
Blank (volker.blank@mcgill.ca). Plasmids generated in this study are available from the Lead Contact without restriction.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Tissue Microarray and Patient Samples
Colon cancer tissue microarray (Col150CS-01) was purchased from Amsbio, including 75 colon adenocarcinoma samples with
matched normal adjacent tissues samples. Sections were deparaffinized inside an immunostainer. Antigen recovery was conducted
using heat retrieval (Heat-Induced Epitope Retrieval) with CC1 (VentanaMedical Systems proprietary cell conditioner using a high pH
buffer) for about 1 hour. Sections were then incubated with 100 mL of anti-NFE2L3 antiserum (see below) for 8 hours at room tem-
perature. An amplification kit (760-080, Ventana Medical Systems - Roche) including rabbit anti-mouse IgG heavy and light chains
andmouse anti-rabbit IgG heavy chains to bind to the primary antibody was applied to increase the staining intensity. Specific signal
was acquired using DABmap detection kit (760-124, Ventana Medical Systems - Roche) according to provider’s recommendations
and a Biotin-SP-conjugated Affinipure Donkey Anti-Rabbit IgG (Jackson Immuno Research, 1/100) for 1 hour at room temperature.
Slides were counterstained manually with Hematoxylin. Stained slides were coverslipped and scanned using the Hamamatsu’s
NanoZoomer Digital Pathology system 2HT. We obtained five matched normal and colorectal tumor tissue samples from patients
from the Jewish General Hospital Central Biobank (Montreal) with appropriate informed consent after approval by the Research
Ethics Committee. The patients 298, 773 and 953 were male while the patients 315 and 626 were female. To determine the expres-
sion levels of NFE2L3 mRNA, the AllPrep DNA/RNA/Protein Mini Kit (QIAGEN) was used following manufacturer’s instructions.
Mouse Xenograft Study
Six- to seven-week-old female athymic nu/nu mice (Harlan) were inoculated with 2.5 3 106 HCT116 human colorectal cancer cells
suspended inMatrigel: PBS (1:1; BD Biosciences) subcutaneously into their right flank. Tumor growth wasmonitored three times per
week in three dimensions using a digital caliper. Tumor volumes were calculated with the modified ellipsoidal formula (LxWxH)/2,
where L is length, W is width and H is height. Xenografts were harvested for subsequent analyses when they reached 0.5 cm3.
Mice were housed under pathogen-free conditions, with food and water provided ad libitum. Procedures involving animals and their
care were conducted according to McGill University guidelines, which are set by the Canadian Council on Animal Care.
Cell Lines
The HCT116 (from male) and HT29 (from female) human colon carcinoma cell lines used in this study were obtained from the
American Type Culture Collection. These cells were cultured in RPMI 1640 media (Invitrogen) supplemented with 10% fetal bovine
serum, 100 units/ml penicillin and 100 mg/ml streptomycin at 37C with 5% CO2.Cell Reports 29, 1469–1481.e1–e9, November 5, 2019 e4
METHOD DETAILS
Reagents
TNFwas purchased from Invitrogen and the inhibitors of the NF-kBpathway, BAY 11-7082 and JSH-23 were bought fromSanta Cruz
and Cedarlane, respectively. LY294002 and PD98059 were purchased from NEB and SB-202190 from Calbiochem.
Lentivirus-Based Transduction of Cells with shRNA
Glycerol stocks of shRNA hairpins were obtained from the Sigma Mission library and isolation of plasmids was carried out with the
PureLinkHiPure PlasmidMaxiprep Kit (Invitrogen). HEK293T cells were seeded 24 hours before transfection. For each 10-cm dish,
0.5 mL 2xHeBS (274 mM NaCl, 10 mM KCl, 1.5 mM Na2HPO4.2H2O, 12 mM Dextrose, 50 mM HEPES in 500 mL MilliQ water at pH
7.01) was added into a sterile eppendorf tube. In another sterile eppendorf tube, 3 mg of plasmid DNA of interest, 2 mg of packaging
vector pCMV-dR8.91, 1 mg of pCMV-VSV-G envelope vector, 60 ml of 2 M CaCl2 and distilled water were added to bring up to 0.5 ml.
The CaCl2/plasmid DNAmix was added to the 2xHeBS and incubated for 20 min and then added to the cells. Mediumwas refreshed
after 16 hours. The supernatant of HEK293T cells containing lentivirus was collected after 24 hours to infect cells with 5 mg/ml
polybrene (Millipore) for 24 hours. The medium was refreshed after lentivirus infection and the cells were selected with puromycin
and/or hygromycin. Individual shRNA vectors used were collected from the human TRC library (Sigma): TRC2 pLKO.5-puro Non-
Target shRNA Control (NTC; SHC216); NFE2L3 sh1: TRCN0000430385; NFE2L3 sh2: TRCN0000013488; RELA sh1:
TRCN0000014684; RELA sh2: TRCN0000014683; NFKB1 sh1: TRCN0000006517; NFKB1 sh2: TRCN0000006518; NFKB2 sh1:
TRCN0000356047; NFKB2 sh2: TRCN0000355955; REL sh1: TRCN0000039984; REL sh2: TRCN0000039983; RELB sh1:
TRCN0000014713; RELB sh2: TRCN0000014714. The pLV-Hygro-CMV-hNFE2L3[NM_004289.6], the corresponding empty vector,
the pLV[shDUX4]-Hygro-U6 (CGAGTGGCTTTGCCCTCCCGA) and the pLV[scramble shRNA]-Hygro-U6 (CCTAAGGTTA
AGTCGCCCTCG) were synthesized and cloned by VectorBuilder. We generated the AB and C mutants of NFE2L3 by mutating
the pLV-Hygro-CMV-hNFE2L3 using Quikchange II XL (Agilent, 200522). The mutations targeting critical regions responsible for
the generation of NFE2L3 A, B and C forms will be described in a different manuscript, Saliba et al., currently in preparation.
RNA Extraction and RT-qPCR
Total RNA was extracted using the TRizol-chloroform (Invitrogen) extraction method. Samples were digested with DNase I (Roche).
cDNA was prepared using EasyScript Plus cDNA Synthesis Kit (Abmgood) according to the manufacturer’s instructions. Transcript
abundance was determined by qPCR using SsoAdvanced SYBR Green supermix (Bio-Rad) with primers in Table S2. qPCR analysis
was performed in a CFX96 Touch Real Time PCR detection system (Bio-Rad). Data were analyzed by the threshold cycle (Ct)
comparative method and normalized to ACTINB and GAPDH genes.
Immunoblot
Cells were lyzed with whole cell lysis buffer [10 mM Tris-HCl, pH 8.0, 420 mMNaCl, 250 mM sucrose, 2 mMMgCl2, 1% Triton X-100,
1/100 cOmplete EDTA-free protease inhibitor cocktail (Roche), 1/25 PhosSTOP (Roche)] for 20 min on ice. Protein extracts were
separated on CriterionTM XT (Bio-Rad) 4%–12%Bis-Tris gradient or Tris-glycine gels according tomanufacturer’s instructions. Pro-
teins were then transferred to the PVDF membrane (Immobilon-P, Millipore) in a wet transfer system in the absence of methanol.
Membrane was blocked for 2-6 hours at room temperature in 5% milk in 1X TBS-T (50 mM Tris-HCl, pH 7.6, 200 mM NaCl, 0.05%
Tween 20) and incubated with primary antibody overnight at 4C. After 3 washes with 1X TBS-T, membrane was incubated for 1 hour
with secondary antibody and washed at least 6 times with 1X TBS-T. The proteins were detected by ImmobilonTM Western Chemi-
luminescent HRP substrate fromMillipore according to instructions. We used an antiserum specific for a peptide (ENSLQQNDDDEN
KIAEKPDWEAEK) of NFE2L3 (Kannan et al., 2015). The peptide was coupled to keyhole limpet hemocyanin and used to immunize
female New ZealandWhite rabbits (Pocono Farms). The serumwas purified using peptide coupled to Affi-Gel 10 (Biorad). Antibodies
specific for the following proteins were purchased from Santa Cruz: Pol II (sc-899), RELA (sc-109), NFKB1 (sc-7178), REL (sc-70),
RELB (sc-226), DUX4 (sc-376490), CDK1 (sc-53) and HA-tag (sc-7392). The antibodies specific for NFKB2 (4882), p-RELA (3033),
p-NFKBIA (2859), Myc-Tag (2276) and NUP98 (2598) were purchased from Cell Signaling. The antibody specific for a-tubulin
(T6074) was purchased from Sigma. The His-tag antibody (34660) was purchased from QIAGEN and the p-H1 (05-1324) antibody
was purchased fromMerck Millipore. Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Pierce
and the VeriBlot Detection reagent (ab131365, Abcam) was used for immunoprecipitation.
Cell Proliferation and Survival Assay
BrdU incorporation assay was performed using the BrdU Cell Proliferation ELISA Kit (colorimetric) (Abcam). Briefly, HCT116 and
HT29 cells were cultured in 96-well plates at a density of 1 3 103 cells/100 ml/well in complete growth media. After 60 hours, cells
were labeled using 1x BrdU and incubated overnight at 37C in a humidified atmosphere. After incubation, the culture medium
was removed and cell DNA was denatured in one step by adding the fixing solution. Subsequently, the cells were incubated with
the primary anti-BrdU monoclonal detector antibody for 1 hour at room temperature. Peroxidase Goat Anti Mouse IgG Conjugate
was added after one washing step. After the removal of the antibody conjugate, the cells were washed and the TMB Peroxidase sub-
strate was added for 30 min. The reaction product was quantified by measuring the absorbance using a microplate reader (Fluostare5 Cell Reports 29, 1469–1481.e1–e9, November 5, 2019
Optima, BMG Labtech) at 450 nm.MTT assay was performed to detect cell viability after 72 hours by using Thiazolyl Blue Tetrazolium
Bromide (MTT, Sigma) following the manufacturer’s recommendations with an incubation of 4 hours at 37C.
Clonogenic and Soft Agar Assays
For clonogenic assays, HCT116 and HT29 cells were plated at low density (13 103 cells per 6 cm dish) in fresh media. After 10 days,
cells were stained with 0.5% (w/v) crystal violet in 25% methanol, and the number of colonies was counted. A soft agar assay was
used tomeasure cell anchorage-independent growth. Cells were seeded into 6-well plates (coated with a basal layer made of 2mL of
0.6% low-melting-point agarose) at 3 3 104 cells per well in 2 mL of 0.3% low-melting-point agarose containing 20% FBS). Two
weeks after incubation, colonies were photographed and counted with an inverted microscope (Zeiss Primovert) equipped with a
camera (Zeiss Axiocam ERc 5 s).
Apoptosis and Cell Cycle Analysis
The HCT116 and HT29 cell lines were trypsinized, centrifuged, aliquoted into tubes and labeled with annexin V and propidium iodide
using an apoptosis detection kit (Sigma). Annexin V and PI staining were performed following the manufacturer’s recommendations
and analyzed with a BD FACSCalibur flow cytometer. For cell cycle analysis, subconfluent cells were synchronized by incubation in
RPMI without FBS for 48 hours. Synchronized cells were then stimulated to proliferate by the addition of RPMI supplemented with
10% FBS. Cells were collected after 16 hours and fixed in 70% ethanol at 20C overnight. The cells were washed with cold PBS,
treated with 0.1 mg/ml of RNase A (Invitrogen), and stained with 50 mg/ml of propidium iodide (Sigma). Cell cycle profiles were
analyzed by flow cytometry using the BD LSR Fortessa.
Immunohistochemistry
Immunohistochemical staining against NFE2L3 and MKI67 was carried out on paraffin-embedded formalin-fixed samples using the
automated Bond RX staining platform from Leica Biosystems, Australia. Sections were deparaffinized inside an immunostainer. An-
tigen recovery was conducted using heat retrieval (Heat-Induced Epitope Retrieval) with ER2 (Leica Biosystems proprietary Epitope
Retrieval using a high pH buffer) for 40 min. Sections were then incubated with 150 mL of anti-NFE2L3 antiserum (described above,
1/50) and 150 mL of anti-MKI67 antibody (Biocare Medical #CRM 325 A, 1/100) for 15 min at room temperature. Detection of specific
signal was acquired by using Bond Polymer DAB Refine kit (#DS9800, Leica Biosystems) according to provider’s recommendations.
Slides were counterstained automatically with Hematoxylin included in the Polymer DAB kit. Stained slides were coverslipped and
scanned using the Hamamatsu’s NanoZoomer Digital Pathology system 2HT.
ChIP-qPCR and ChIP-Seq
HCT116 cells were cross-linked using 1% formaldehyde for 10 min at room temperature and quenched with glycine to a final con-
centration of 0.125 M for 5 min. Subsequently, the cells were lysed in lysis buffer (50 mM Tris HCl, 50 mM NaCl, 5 mM EDTA, 0.1%
SDS, 0.5% deoxycholate, 0.5% Triton X-100 and 0.5% NP-40), which was followed by chromatin shearing using a Fisher Scientific
model 500 sonic dismembrator. The samples were then incubated overnight with SureBeads Protein A magnetic beads (Bio-Rad)
blockedwith salmon spermDNA (Invitrogen) with the desired antibodies: anti-RELA (Santa Cruz, sc-109X) or anti-NFE2L3 (described
above). Normal rabbit IgG (Santa Cruz, sc-2027) and/or input was used as a negative control. After stringent washes, chromatin was
eluted in elution buffer (50 mM Tris HCl, 1 mM EDTA and 1% SDS). Eluates were reverse cross-linked overnight at 65C and
deproteinated with Proteinase K for 1 hour at 42-45C followed by 15 min at 65C. DNA was extracted and purified via phenol-chlo-
roform-isoamyl alcohol extraction and ethanol precipitation. ChIP-qPCR analyses were performed in a CFX96 Touch Real Time PCR
detection system (Bio-Rad) and the following primers were used: NFE2L3 (forward 50-CCACAGTCATTCACAACGGA-30 and reverse
50-GCAGCTGTTCCATACGTTTACA 30), DUX4 (forward 50-TCACCTTTGTCATCAGTTCAGG-30 and reverse 50-TGATGTAACTC
TTGTCTAAGCTCTGC 30). Fold induction was calculated over IgG. ChIP-seq libraries were prepared according to the NEBNext
protocol and sequenced using Illumina HiSeq 2000. For the ChIP-seq analysis, HCT116 cells were treated with TNF (20 ng/ml,
6 hours). Trimming and clipping were performed using Trimmomatic. Reads were trimmed from the 30 end to have a phred score
of at least 30. Illumina sequencing adapters were removed from the reads, and all reads were required to have a length of at least
50 bp. The filtered reads were aligned toHomo sapiens assembly hg19. Each readset was aligned using BWAwhich creates a Binary
AlignmentMap file (.bam). Quality filteringwas then performed using SAMtools (Li et al., 2009). All alignments withMAPQ smaller than
20 and samflag 4 (read unmapped) were excluded. HOMER (Heinz et al., 2010) was used to create QC Tag Directories, to compute
ChIP-seq Quality Metrics and to generate BedGraph Track Format files that were loaded in UCSC. Peaks were called using MACS
software with default parameters. The peaks called were annotated with HOMER using RefSeq annotations. Gene ontology and
genome ontology analyses were also performed at this stage.
Dual-luciferase Reporter Assay
Promoter region was cloned into pGL3 Basic Luciferase Reporter (Promega) by digesting plasmid and annealed primer pair using
KpnI-HF RE-Mix (R3142S, NEB) and XhoI (R0146S, NEB) and ligating them with T4 DNA ligase (M0202S, NEB). The forward
primer was:CCACAACGGATGAAGCATGCATTCTTCCAAGTAACACACAGGTTAAACAAAGAAATGAACAGTTTTTGTAGAATTGAAT
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TGTGTGTTACTTGGAAGAATGCATGCTTCATCCGTTGTGGGTAC. The construct was confirmed by DNA sequencing. Aliquots of
5 3 104 293T cells were seeded into 24-well plates. After 24 hours, 250 ng of each independent luciferase reporter plasmid plus
50 ng of pRL-TK (Promega) plasmid as the control were co-transfected with 125 ng, 250 ng or 500 ng of the pCMV4-RELA, or control.
Luciferase activity was then measured 24 hours after transfection using the Dual-Luciferase Reporter Assay System with a GloMax
Luminometer (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity for each transfected cell sample.
(Co-)Immunoprecipitation
HCT116 cells were transfected with pCMV6-entry-Myc-Flag (PS100001, Origene) or pCMV6-DUX4-Myc-Flag (RC238145, Origene)
using X-tremeGene 9 DNA transfection reagent (Roche). Cells were lysed with IP buffer (50 mMTris-HCl pH 7.9, 1 mMEDTA, 0.1 mM
EGTA, 12.5mMMgCl2, 400mMNaCl, 20%glycerol, 0.1%SDS, 1%Triton X-100 and a complete-EDTA free protease inhibitor) on ice
for 15min and then sonicated 20 s at the lowest intensity. Cell lysates were clarified by centrifugation at 14,000 rpm for 1min. Clarified
lysates were incubated for 1 hour at 4Cwith anti-Flag M2 affinity gel (Sigma, A2220). After three washes with IP buffer, proteins from
immunoprecipitations were resolved by SDS polyacrylamide gel electrophoresis (PAGE), visualized by colloidal Coomassie stain and
excised from the gel before mass spectrometry analysis. For the co-immunoprecipitation, HCT116 cells were transfected with
pCMV-neo-CDK1-HA, pCMV-neo-CDK2-HA, pCMV-neo-CDK4-HA, pCMV-neo-CDK6-HA (Addgene) (van den Heuvel and Harlow,
1993) pCMV6-entry-Myc-Flag and pCMV6-DUX4-Myc-Flag (Origene). For the experiment with DUX4 mutants, HCT116 cells were
transfected with pcDNA3.1-Myc, pcDNA3.1-DUX4(WT)-Myc, pcDNA3.1 DUX4(D111-131)-Myc, pcDNA3.1 DUX4(D141-180)-Myc
and pcDNA3.1 DUX4(D381-400)-Myc, pcDNA3.1 DUX4(Arg117Ala)-Myc, pcDNA3.1 DUX4(Phe118Ala)-Myc (Genscript), pCMV-
neo-CDK1-HA (Addgene) and pCMV-neo-HA (Clontech). Cells were lyzed with IP buffer on ice for 15 min and then sonicated 20 s
at the lowest intensity. Cell lysates were clarified by centrifugation at 14,000 rpm for 1 min and were incubated for 2 hours with
anti-HA antibody (2 mg/ml of cell lysate, sc-7392, Santa Cruz) followed by 2 hours with protein A and G Sepharose (Millipore) at
4C. Before immunoprecipitation, protein A and G Sepharose were blocked for 1 hour at 4C in IP buffer containing 2.5% BSA,
0.16 mg/ml salmon sperm DNA and 0.16 mg/ml E. coli tRNA. Then, all immunoprecipitates were washed three times in IP buffer, de-
natured at 95C for 10 min and separated on 12% SDS-PAGE for western blot analysis. For endogenous protein immunoprecipita-
tions, HCT116 cells were transduced with shNFE2L3-1. Cells were lyzed with the IP buffer. For each condition, CDK1 antibody
(2 mg/ml of cell lysate, sc-54, Santa Cruz) or mouse pre-immune serum (2 mg/ml of cell lysate, sc-2025, Santa Cruz) were incubated
for 2 hours at 4C. Then, we followed the same protocol already described above.
Mass Spectrometry
Destaining was performed in 50% MeOH. Bands were shrinked in 50% acetonitrile (ACN) and reconstituted in 50 mM ammonium
bicarbonate with 10 mM TCEP and vortexed for 1 hour at 37C. Chloroacetamide was added for alkylation to a final concentration
of 55mM. Samples were vortexed for another hour at 37C.One mg of trypsin was added and the digestion was performed for 8 hours
at 37C. Peptide extraction was conducted with 90% ACN. Extracted peptide samples were dried down and solubilized in ACN 5%
formic acid (FA) 0.2%. Samples were loaded on a homemadeC18 precolumn (0.3mm i.d. x 5mm) connected directly to the switching
valve and separated on a homemade reversed-phase column (150 mm i.d. x 150 mm) with a 56 min gradient from 10%–30% aceto-
nitrile (0.2% FA) and a 600 nl/min flow rate on a Ultimate 3000 nano-LC (Dionex) connected to a Q-Exactive Plus (Thermo Fisher Sci-
entific). Each full MS spectrum acquired with a 70,000 resolution was followed by 12 MS/MS spectra, where the 12 most abundant
multiply charged ions were selected for MS/MS analysis. TandemMS experiments were performed using HCD at collision energy of
25%. The data were processed using PEAKS 7.0 (Bio-informatics Solutions) and the human Uniprot database. Tolerances on pre-
cursors and fragments were 10 ppm and 0.01 Da, respectively. Variable selected post-translational modifications were carbamido-
methyl (C), oxidation (M), deamidation (NQ) and phosphorylation (STY). MS hits were analyzed for enrichment using ReactomePA (Yu
and He, 2016).
Prediction of DUX4 Structure using Fold Recognition Domain
Since no crystallographic structure of DUX4 alone is available in the PDB (Protein Data Bank), a model of the protein has been gener-
ated based on fold recognition. Sequence of human DUX4 (UniProtKB: Q9UBX2) was obtained from UniProt database (The UniProt
Consortium, 2017). DUX4 protein is composed by 424 amino acids for a molecular weight of 44.94 kDa. A model of this protein was
build using I-TASSER (a web app designed for 3D structure prediction based on fold recognition) (Roy et al., 2010; Yang et al., 2015;
Zhang, 2008).The target sequence has been threaded through a non-redundant PDB structure library by LOMETS (Local Meta-
Threading-Server) in order to identify template structures that may have a similar structure or similar structural motif to the query pro-
tein. If homologous templates are identified, a template-based fragment assembly procedure (threading, fragment assembly, and
iteration) is used to construct full-length models. The outputs of the I-TASSER modeling contain the top 5 models predicted for
the query sequence. Each model is associated to C-score and TM-score. C-score is a confidence score for estimating the quality
of predicted models. TM-score reflects the structural similarity between two structures taking into account RMSD (Root-Mean-
Square Deviation) between two atoms or residues. RMSD is sensitive to local error, including misorientation of side chains, tails,
and random coils, which can increase RMSD values while the global topology is correct. A correction is applied tominimize the effect
of local errors. Top 5 predicted models show two groups of structure regarding to general topology, C-score (model with a high con-
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very similar structure and high scores. A structure superposition confirmed that these 3models are very close to each other with slight
changes in the random coils region. The second group is less relevant with low scores and a poor recovery with PDB templates. A
predicted model with higher C-score value and TM-score value (model 3) was kept for further investigation.
Modeling DUX4-CDK1 Complex
Based on biological evidence, a model of DUX4-CDK1 complex has been built using ZDOCK 3.0.2. (Mintseris et al., 2007; Pierce
et al., 2011). This software studies all possible binding modes by translation and rotation of each protein. We carried out this eval-
uation by using an energy-based scoring function called IFACE. The score depends on statistical potential, shape complementarity,
electrostatic, and an experimental unbound protein benchmark. To start the modeling, we searched a similar complex to the one
studied in the PDB. We found a comparable structure, the complex of CDK1-Cyclin B1-CKS2 with a small molecule named
NU6102 (PDB: 5LQF) (Coxon et al., 2017). In order to validate the docking, each protein from structure 5LQF was individualized in
a file (CDK1, Cyclin B1 and CKS2). Each protein was structurally prepared using Biovia Discovery Studio 2016. The three proteins
were docked together using ZDOCK and the result show an identical overlay with the complex present in the PDB (slight changes
in random coils regions). The second step consists in the creation of the query complex. For this, the 3D model of DUX4 was
used as input in ZDOCK with CDK1 and Cyclin B1. The complex with the highest ZDOCK-score shows identical protein-protein in-
teractions (PPIs) between CDK1 and Cyclin B1 and a complete overlay for these two proteins compared to the reference structure
5LQF. DUX4 has been shown to interact with CDK1 at the same regions as CKS2 with similar interactions (hydrophobic at the core of
the surface interaction and electrostatic at the borders).
In Vitro Protein Interaction (GST Pull-down Assay)
Recombinant DUX4-Myc-FLAG was produced in HEK293 cells transiently transfected using the calcium phosphate method with
15 mg (10 cm) of pCMV6-DUX4-Myc-FLAG and then immunoprecipitated with anti-FLAG M2 Affinity Gel (Sigma-Aldrich), washed
three times for 5 min in 1X TBS, eluted for 1 hour at 4C with 250 ng/ml of FLAG peptide (Sigma-Aldrich) in 1X TBS and protein
concentration was evaluated using a NanoDrop2000c spectrophotometer (A280). In vitro protein interactions were performed as
previously described (Lessard et al., 2018). GST (100 ng according to company; SRP5348, Sigma-Aldrich) or GST tagged human
active CDK1/cyclin B1 (300 ng according to company; SRP5009, Sigma-Aldrich) or GST tagged human CDK1 (300 ng according
to company; C22-14G, Signal Chem) were incubated with human recombinant DUX4-Myc-FLAG (200 ng) in 300 mL of PB buffer
(20 mM HEPES, pH 7.5, 130 mM KCl, 5 mM MgCl2, 1 mM DTT, 0.5 mM EDTA, 0.05% NP40) and mixed using a rotating machine
at 30C for 2 hours. Proper amounts of glutathione-Sepharose beads (17-0756-01, GE Healthcare) were washed three times with
PB buffer. Then, 10 mL of glutathione beads and 5 mL of BSA (25% stock solution) were added to proteins mix and incubation
continued at room temperature for 30 min with rotation. The beads were then washed three times for 15 minutes with PB buffer
at room temperature with rotation. Then, the appropriated quantity of 6X loading buffer (0.5 M Tris-HCl pH 6.8, 30% glycerol, 10%
SDS, 1% bromophenol blue and 15% b-mercaptoethanol) was added. The samples were boiled for 5 min and separated by SDS-
PAGE for western blotting.
Purification of GST-DUX4
Plasmid coding for human DUX4 (pGEX-6-p1, N-term GST-HRV 3V protease cleavage site) was a gift from Professor Scott Harper
(Nationwide Children’s Hospital, USA). The plasmid (10 ng) was transformed into the bacterial strain E. coli BL21 (DE3). The trans-
formed cells were plated on LB plates containing ampicillin (100 mg/ml) and incubated overnight at 37C.One colony was picked from
one of the plates and used to inoculate 5 mL of LB broth containing 100 mg/ml ampicillin. The culture was grown overnight at 37C
with shaking at 250 rpm. A bacterial stab was prepared by adding 150 mL of cell culture to 850 mL of glycerol 50% (sterile). Aliquots
were kept at80C. Preculture (x2) was prepared by inoculating 250 mL of bacterial stock to 5mL of TBmedium (yeast extract 24 g/L,
tryptone 20 g/L, glycerol 0.4% (V/V), 0.017 M KH2PO4 and 0.072 M K2HPO4) with ampicillin 100 mg/mL. Culture was grown overnight
at 37C with shaking. For production of GST-fusion protein, culture was divided into equal amounts between four flasks containing
250 mL TB/Amp medium and allowed to grow at 37C to A600 = 0.6. The culture was induced with 0.1 mM isopropyl b-D-1-thioga-
lactopyranoside (IPTG) and growth was continued overnight at 20C with agitation. Induced culture was centrifuged at 6000 x g for
20min. Cell pellet was resuspended in 60mL of Lysis buffer (50mMTris-HCl pH 8.0, 150mMNaCl, 0.1mMEDTA, 0.1%Triton X-100,
1 mM DTT, RNase and protease inhibitor cocktail (Complete, 1 tablet for 50 mL of solution, Roche). Cells were lysed on ice by son-
ication using a cell disrupter. Crude extract was centrifuged at 9000 rpm for 45 min at 4C to recover the lysate. The supernatant was
filtered through 0.45 mm and 0.2 mm filters. Proteins lysate was loaded onto a 1 mL GSTrap FF (GE Healthcare) equilibrated with
50 mM Tris-HCl pH 8.0, 400 mM NaCl, 0.1 mM EDTA, 1 mM DTT and 5% glycerol. The charged column was washed with the equil-
ibration buffer until a stable baseline was attained. Target protein was eluted with elution buffer (50 mM Tris-HCl pH 8.0, 400 mM
NaCl, 0.1 mM EDTA, 1 mM DTT, 5% glycerol and 10 mM reduced gluthatione). After elution, appropriate fractions were pooled
and the buffer was changed (50mMTris-HCl pH8.0, 150mMNaCl, 0.1mMEDTA, 1mMDTT and 5%glycerol) using PD-10 desalting
column (GE Healthcare). Protein concentration was determined using NanoDrop and flash freeze in liquid nitrogen for storage
(80C) until use.Cell Reports 29, 1469–1481.e1–e9, November 5, 2019 e8
Microscale Thermophoresis (MST)
MST measurements were performed on a Nanotemper Monolith NT.115 instrument (Nano- temper Technologies, GmbH) using His-
tag fluorescent labeling. Recombinant human CDK-1 protein (187447, Abcam) purified to homogeneity, was freshly labeled with the
Monolith His-Tag RED-tris-NTA labeling dye (2nd generation) according to the supplied protocol (Nanotemper Technologies, GmbH).
Measurements were performed in PBS pH 7.4 containing 2.5% glycerol, 5 mM GSH, 0.5 mM DTT and 0.05% Tween-20 in standard
treated capillaries (MO-K022, Nanotemper Technologies, GmbH). The final concentrations of CDK-1 in the assay were 50 nM. DUX-4
was then titrated in 1:1 dilutions following manufacturer’s recommendations. GST protein (SRP5348, Sigma) was used as negative
control. All reactions medium underwent brief centrifugation at room temperature followed by 5 min incubation at 25C after loading
into capillaries. Measurements were performed at 25C in triplicates using 40% LED power and medium MST power, LaserOn time
was 20 s, Laser Off time 3 s.
Kinase Assay
HCT116 cells were transduced with a combination of vectors driving non-silencing controls (NTC shRNA or pLV scramble),
shNFE2L3-1 or shDUX4. The same number of cells was lyzed in the same volume of IP buffer for each condition. Lysates were incu-
bated for 2 hours at 4C with antibody against CDK1 (2 mg/ml, sc-54, Santa Cruz). For the kinase assay, we used the same protocol
described above for the co-immunoprecipitation but subsequently, immunoprecipitates were washed three times in kinase buffer
(9802, Cell Signaling) and then incubated at 30C for 30 min with 40 ml of kinase buffer containing 200 mM ATP (9804, Cell Signaling)
and 2 mg of recombinant human Histone H1 (His tag N terminus) protein (198676, Abcam). Finally, reactions were stopped by heating
at 95C for 10 min and separated on 12% SDS-PAGE for western blot analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Methods
All data are shown asmean values ± standard error of the mean (SEM) unless indicated otherwise. Sample numbers of data obtained
from animal experiments refer to the number of individual mice, as specified in the figure legends. Statistical analysis (two-tailed Stu-
dent’s t test) was performed using Excel and Mann–Whitney U test was performed using Statistica software (StatSoft, Tulsa, OK), as
indicated in the figure legends. A value of p < 0.05 was considered statistically significant.
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Figure S1
Figure  S1: NFE2L3 upregulation in colon cancer, related to Figure 1. (A) Bar graph presenting z-scores of relative 
microarray expression of NFE2L3 in various human tissue samples. Data collected from www.biogps.org (McCall et al., 
2011; Wu et al., 2009). Error bars represent the median absolute deviation. (B) NFE2L3 expression in multiple cancer 
microarray data sets available in Oncomine (Rhodes et al., 2004). (C) The median NFE2L3 rank was assessed across 12 
analyses comparing the normal tissue group to each colorectal cancer data sets. The p-value is given for the median-
ranked analysis (www.oncomine.org).
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Figure S2
Figure S2: NFE2L3 knockdown does not induce apoptosis, related to Figure 2. (A) Comparison of flow cytometry 
histograms of Annexin V and propidium iodide stained HCT116 cells transduced with a NTC shRNA or NFE2L3-
specific shRNAs (shNFE2L3-1 or -2). (B, C) Annexin V/PI based apoptosis analysis in NTC shRNA or NFE2L3-
specific shRNAs (shNFE2L3-1 or -2) transduced HCT116 and HT29 cells. Error bars are means ± SEM, n = 3 
independent experiments.
N
TC
 s
hR
N
A
sh
R
EL
A
1
sh
R
EL
A
2
N
TC sh
R
EL
A
1
sh
R
EL
A
2
NFE2L3
RELA
Tubulin
TNF
B
HCT116
N
TC
 s
hR
N
A
sh
R
EL
A
1
sh
R
EL
A
2
N
TC sh
R
EL
A
1
sh
R
EL
A
2
NFE2L3
RELA
Tubulin
TNF
C
HT29
N
TC
 s
hR
N
A
sh
R
EL
1
sh
R
EL
2
N
TC
sh
R
EL
1
sh
R
EL
2
NFE2L3
REL
Tubulin
TNF
E
N
TC
 s
hR
N
A
sh
R
EL
B
1
sh
R
EL
B
2
N
TC sh
R
EL
B
1
sh
R
EL
B
2
NFE2L3
RELB
Tubulin
TNF
D
N
TC
 s
hR
N
A
sh
N
FK
B1
 1
sh
N
FK
B1
 2
N
TC
NFE2L3
p105
Tubulin
TNF
F shN
FK
B1
 1
sh
N
FK
B1
 2
p50
N
TC
 s
hR
N
A
sh
N
FK
B2
 1
sh
N
FK
B2
 2
N
TC
NFE2L3
p100
Tubulin
TNF
G shN
FK
B2
 1
sh
N
FK
B2
 2
p52
0
0,5
1,0
1,5
2,0
2,5
NFĸB subunits
NFE2L3
CDKN1A
m
R
N
A 
re
la
tiv
e 
ex
pr
es
si
on
 le
ve
l
A
3,0
N
TC
 s
hR
N
A
sh
R
EL
A-
1
sh
R
EL
A-
2
N
TC
 s
hR
N
A
sh
R
EL
B-
1
sh
R
EL
B-
2
N
TC
 s
hR
N
A
sh
R
EL
-1
sh
R
EL
-2
N
TC
 s
hR
N
A
sh
pN
FK
B1
-1
sh
pN
FK
B1
-2
N
TC
 s
hR
N
A
sh
pN
FK
B2
-1
sh
pN
FK
B2
-2
HCT116
HCT116
HCT116 HCT116
Figure S3
Figure S3: NFE2L3 is principally regulated by the RELA subunit of NF-κB, related to Figure 3. (A) Quantitative 
reverse transcription PCR analysis of transcripts of NF-ĸB family members, NFE2L3 and CDKN1A (p21) in HCT116 
cells transduced with a NTC shRNA, or RELA-specific shRNAs (shRELA-1 or -2), or RELB-specific shRNAs 
(shRELB-1 or -2), or REL-specific shRNAs (shREL-1 or -2), or NFKB1-specific shRNAs (shNFKB1-1 or -2) or 
NFKB2-specific shRNAs (shNFKB2-1 or -2) (mean ± SD). (B, C) Immunoblot analysis of NFE2L3 in HCT116 and 
HT29 cells transduced with a NTC shRNA or RELA-specific shRNAs (shRELA-1 or -2) untreated or treated with TNF 
(20 ng/ml, 6 hours). (D-G) Immunoblot analysis of NFE2L3 in HCT116 cells transduced with a NTC shRNA or RELB-
specific shRNAs (shRELB-1 or -2) (D), or REL-specific shRNAs (shREL-1 or -2) (E), or NFKB1-specific shRNAs 
(shNFKB1-1 or -2) (F), or NFKB2-specific shRNAs (shNFKB2-1 or -2) (G) untreated or treated with TNF (20 ng/ml, 6 
hours).
Figure S4
Figure S4: NFE2L3 is implicated in the phenotype of RELA knockdown cell line, related to Figure 3. (A) ChIP-
seq data from the ENCODE project consortium showing RELA occupancy over promoter regions of NFE2L3 was 
extracted from the UCSC genome browser; ChIP-seq data from various tissues and cells; Input is shown for reference. 
(B) Immunoblot analysis of HCT116 cells transduced with a NTC shRNA or RELA-specific shRNA (shRELA-1) upon 
reexpression of the different forms of NFE2L3 (see Figure 2C for description of A, B or C form). (C) BrdU 
incorporation in HCT116 cells an in (B) assessed by ELISA. Error bars are mean ± SEM, n = 3 independent 
experiments, *p<0.05, **p<0.01, ***p<0.001, NS = not significant, two-sided Student’s t-test.
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Figure S5
Figure S5: DUX4 expression in patient samples and pathway enrichment analysis of DUX4 protein IP , related to 
Figures 1, 4  and 5. (A) DUX4 mRNA expression in colon cancer and adjacent normal tissue of five different colon 
adenocarcinoma patients (mean ± SD) as analyzed by quantitative reverse transcription PCR analysis. See Figure 1B for 
comparison with NFE2L3 mRNA expression in the same patient tissue samples. (B) Dotplot of the top 40 pathways 
enriched among DUX4 immunoprecipitated proteins. Data was analyzed using ReactomePA with a qvalue cutoff of 
0.05 calculated using the Benjamini-Hochberg procedure. 
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Figure S6
Figure S6: Potential DUX4-CDK1 interactions and comparison with the other CDK family members, related to 
Figure 5. (A) Representation of the ternary complex of DUX4-CDK1-Cyclin B1 by using ZDOCK software with the 
highest C- and TM-scores. (B) Summary of amino acids and type of bonds implicated in the interaction between DUX4 
and CDK1. (C) Sequence alignment of the different human CDKs: CDK1 (Uniprot accession number P06493), CDK2 
(P24941), CDK4 (11802) and CDK6 (Q00534) based on the EMBL-EBI algorithm MUSCLE. The most conserved 
residues are highlighted in red and the residues that interact with DUX4 are highlighted in green (based on ternary 
complex described in Figure S6A). Orange highlights the amino acids in CDK2, CDK4 and CDK6 at the same position 
as the DUX4-CDK1 interacting residues.
Real-time PCR primers
Name 5' forward primer (5'-3') 3' reverse primer (5'-3')
NFE2L3 TCAGCAGAATGATGATGATGAAA TGTCCCATTCAGATGTCTCTCA
MKI67 AGAAGACAGTACCGCAGATGA CGGCTCACTAATTTAACGCTGG
DUX4 GCGGAGAACTGCCATTCTTTT TCCAGGTTTGCCTAGACAGC
RELA TCATGAAGAAGAGCTCCTTTCAGC CTGGCTTGGGGACAGAAG
RELB GCTCTACTTGCTCTGCGACA GGCCTGGGAGAAGTCAGC
REL TGAACATGGTAATTTGACGACTG ACACGACAAATCCTTAATTCTGC
NFKB1 CCTGGAACCACGCCTCTA GGCTCATATGGTTTCCCATTTA
NFKB2 ACACCGTTGTACAAAGATACGC GGCCCGGCTCTGTCTAGT
ACTINB CCCAACGCACCGAATAGTTACG GCTGCCCATCATCATGACCT
GAPDH TCCCACAGCTGGTACCAATAGGA TCCTGTGGCATGTTTTTGAATCTC
CDKN1A ACCCTTGTGCCTCGCTCAGG GCGTTTGGAGTGGTAGAAATCTGT
Table S2
Table S2, related to STAR Methods: Sequence of qPCR primers
